In a significant development for the management of asthma and chronic obstructive pulmonary disease (COPD) in the Maldives, State Trading Organisation (STO), in partnership with AstraZeneca, has rolled out two transformative respiratory health products: Symbicort Turbuhaler and Pulmicort Respules. The launch event, held on 7th December at the 24th floor of Dharumavantha Hospital, marked a major milestone in improving respiratory health outcomes in the country.
The event, which brought together approximately 60 physicians, featured a keynote address by Dr. Rennis Davis, a renowned pulmonologist from India. Dr. Davis highlighted the importance of adhering to the Global Initiative for Asthma (GINA) guidelines, emphasizing the need to reduce the overuse of short-acting beta-agonists (SABA) and promote maintenance and reliever therapy for improved patient outcomes.
The launch of Symbicort Turbuhaler and Pulmicort Respules represents a significant step forward in addressing critical medical needs in the Maldives. Symbicort Turbuhaler, a cutting-edge dry powder inhaler, offers a user-friendly solution with fast and superior relief compared to traditional SABA relievers. Pulmicort Respules, designed for quick efficacy, dissolve through the airway mucus layer in just six minutes, delivering a strong pulmonary vasoconstrictive effect within 30 minutes. This innovative approach reduces asthma symptoms and the risk of exacerbations, providing an efficient alternative to systemic steroids.
STO’s introduction of these products underscores its commitment to addressing critical medical needs and enhancing healthcare services for the Maldivian community. These solutions represent a major opportunity for improved respiratory health outcomes across the country.
